Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Q&A: an eye on innovation with SparingVision

Paris-based biotech company SparingVision is developing a treatment for retinitsis pigmentosa, which can lead to complete blindness. We sit down with Florence Allouche Ghrenassia, president and CEO of SparingVision, to discuss the future of specialist eye interventions.

Close
Close
Close

Go Top